Ibio, Common Stock Stock Performance
| IBIO Stock | USD 5.08 0.22 4.53% |
IBio, Common holds a performance score of 16 on a scale of zero to a hundred. The firm retains a Market Volatility (i.e., Beta) of 0.81, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, IBio, Common's returns are expected to increase less than the market. However, during the bear market, the loss of holding IBio, Common is expected to be smaller as well. Use iBio, Common Stock downside variance, and the relationship between the sortino ratio and accumulation distribution , to analyze future returns on iBio, Common Stock.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in iBio, Common Stock are ranked lower than 16 (%) of all global equities and portfolios over the last 90 days. In spite of very weak forward indicators, IBio, Common displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (7.00) | Five Day Return (18.56) | Year To Date Return 86.78 | Ten Year Return (99.88) | All Time Return (99.90) |
Last Split Factor 1:20 | Dividend Date 2018-06-11 | Last Split Date 2023-11-29 |
1 | iBio expands cardiometabolic and obesity program Seeking Alpha | 01/02/2025 |
2 | iBio Expands Pipeline with New Antibody Agreement - Yahoo Finance | 01/03/2025 |
3 | iBio and AstralBio Breakthrough Novel Antibody Targets Obesity and Diabetes Through Activin E Inhibition - StockTitan | 01/07/2025 |
4 | iBio, Inc. CFO Felipe Duran Acquires 9,191 Shares of Stock | 01/14/2025 |
5 | Acquisition by Brenner Martin of 700000 shares of Ibio subject to Rule 16b-3 | 01/27/2025 |
6 | iBio GAAP EPS of -0.48 | 02/10/2025 |
7 | Opaleye Management Inc. Acquires Additional Shares in iBio Inc. | 02/14/2025 |
8 | iBio to Begin Trading on the Nasdaq Stock Exchange - GlobeNewswire | 02/20/2025 |
9 | Acquisition by Brenner Martin of 230700 shares of IBio, Common at 3.48 subject to Rule 16b-3 | 02/21/2025 |
10 | Disposition of 37243 shares by Randy Maddux of IBio, Common at 0.6832 subject to Rule 16b-3 | 03/14/2025 |
| Begin Period Cash Flow | 7.6 M |
IBio, |
IBio, Common Relative Risk vs. Return Landscape
If you would invest 242.00 in iBio, Common Stock on December 19, 2024 and sell it today you would earn a total of 266.00 from holding iBio, Common Stock or generate 109.92% return on investment over 90 days. iBio, Common Stock is currently generating 1.4892% in daily expected returns and assumes 7.0615% risk (volatility on return distribution) over the 90 days horizon. In different words, 62% of stocks are less volatile than IBio,, and 71% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
IBio, Common Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for IBio, Common's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as iBio, Common Stock, and traders can use it to determine the average amount a IBio, Common's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2109
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | IBIO | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 7.06 actual daily | 62 62% of assets are less volatile |
Expected Return
| 1.49 actual daily | 29 71% of assets have higher returns |
Risk-Adjusted Return
| 0.21 actual daily | 16 84% of assets perform better |
Based on monthly moving average IBio, Common is performing at about 16% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of IBio, Common by adding it to a well-diversified portfolio.
IBio, Common Fundamentals Growth
IBio, Stock prices reflect investors' perceptions of the future prospects and financial health of IBio, Common, and IBio, Common fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on IBio, Stock performance.
| Return On Equity | -0.84 | ||||
| Return On Asset | -0.3 | ||||
| Operating Margin | (19.48) % | ||||
| Current Valuation | 47.15 M | ||||
| Shares Outstanding | 9.14 M | ||||
| Price To Earning | (2.18) X | ||||
| Price To Book | 3.61 X | ||||
| Price To Sales | 127.98 X | ||||
| Revenue | 225 K | ||||
| Gross Profit | 2.17 M | ||||
| EBITDA | (14.02 M) | ||||
| Net Income | (24.91 M) | ||||
| Cash And Equivalents | 33.52 M | ||||
| Cash Per Share | 3.72 X | ||||
| Total Debt | 4.46 M | ||||
| Debt To Equity | 0.44 % | ||||
| Current Ratio | 1.48 X | ||||
| Book Value Per Share | 2.47 X | ||||
| Cash Flow From Operations | (18.55 M) | ||||
| Earnings Per Share | (4.03) X | ||||
| Market Capitalization | 23.3 M | ||||
| Total Asset | 28.73 M | ||||
| Retained Earnings | (313.85 M) | ||||
| Working Capital | 11.83 M | ||||
| Current Asset | 23.91 M | ||||
| Current Liabilities | 2.29 M | ||||
About IBio, Common Performance
By examining IBio, Common's fundamental ratios, stakeholders can obtain critical insights into IBio, Common's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that IBio, Common is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 6.3 K | 6.6 K | |
| Return On Tangible Assets | (0.96) | (1.01) | |
| Return On Capital Employed | (0.60) | (0.63) | |
| Return On Assets | (0.78) | (0.82) | |
| Return On Equity | (1.05) | (1.10) |
Things to note about iBio, Common Stock performance evaluation
Checking the ongoing alerts about IBio, Common for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for iBio, Common Stock help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| iBio, Common Stock is way too risky over 90 days horizon | |
| iBio, Common Stock appears to be risky and price may revert if volatility continues | |
| iBio, Common Stock has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 225 K. Net Loss for the year was (24.91 M) with profit before overhead, payroll, taxes, and interest of 2.17 M. | |
| iBio, Common Stock currently holds about 33.52 M in cash with (18.55 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.72. | |
| iBio, Common Stock has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: iBio to Begin Trading on the Nasdaq Stock Exchange - GlobeNewswire |
- Analyzing IBio, Common's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether IBio, Common's stock is overvalued or undervalued compared to its peers.
- Examining IBio, Common's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating IBio, Common's management team can have a significant impact on its success or failure. Reviewing the track record and experience of IBio, Common's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of IBio, Common's stock. These opinions can provide insight into IBio, Common's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in iBio, Common Stock. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of IBio, Common. If investors know IBio, will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about IBio, Common listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.03) | Revenue Per Share | Quarterly Revenue Growth (0.88) | Return On Assets | Return On Equity |
The market value of iBio, Common Stock is measured differently than its book value, which is the value of IBio, that is recorded on the company's balance sheet. Investors also form their own opinion of IBio, Common's value that differs from its market value or its book value, called intrinsic value, which is IBio, Common's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IBio, Common's market value can be influenced by many factors that don't directly affect IBio, Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IBio, Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if IBio, Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IBio, Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.